Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Transcode Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 8 | 8 | 0 |
| Shares | 30.9K | 33.5K | +2.64K (+8.6%) |
| Value | $265.7K | $208.1K | −$57.6K (−21.7%) |
New holders (2)
Institutions that held Transcode Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Yorkville Advisors Global, LP | 19,639 | $122.0K | 0.14% |
| FMR LLC | 706 | $4.38K | 0.00% |
Sold out (2)
Institutions that held Transcode Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Geode Capital Management, LLC | 12,740 | $109.7K |
| Royal Bank of Canada | 8 | $0 |